Life Sciences & Healthcare

On September 2, 2020, the German Federal Cartel Office (“FCO”) published its Annual Report 2019/2020 (“Annual Report”) which includes an update on the FCO’s activities in the first half of 2020.[1]

On 2 September 2020, the US Department of Justice Antitrust Division (DoJ), the US Federal Trade Commission, the UK Competition and Markets Authority (CMA), the Australian Competition and Consumer Commission, the New Zealand Competition Commission, and the Canadian Competition Bureau signed a framework agreement to improve cooperation in competition investigations.

The COVID-19 pandemic has caused significant economic disruption, as a consequence of the prolonged and re-occurring shutdowns and the ongoing political and economic uncertainties.

On July 29, 2020, the Monopolies Commission published its Biennial Report XXIII.  The Monopolies Commission makes three main recommendations to strengthen the German and European competition regimes.[1]

On July 27, 2020, the TAR Lazio annulled an ICA decision of September 2019, which fined Com Metodi S.p.A. (“Com Metodi”), Sintesi S.p.A. (“Sintesi”), and Igeam S.r.l., Igeamed S.r.l. and Igeam Academy S.r.l. (jointly, “Igeam”) (together, the “Companies”) for participating in an alleged cartel which affected the outcome of the open tender procedure for the provision of integrated health and safety management services in the workplaces at Italian Public Administrations, launched by Consip S.p.A. (“Consip”) in December 2015 (the “SIC 4 Tender”).[1]

On July 23, 2020, the FCA published its new guidelines on merger control[1] (the “Guidelines”), which came into effect on the same day and therefore replaced the previous guidelines issued in 2013.

Following a public consultation launched in July 2019,[1] the Commission adopted a guidance document[2] on the protection of confidential information in proceedings for the private enforcement of EU competition law based on the Antitrust Damages Directive (“ADD”).[3] The Confidentiality Guidance is intended for use by national courts to ensure consistency across Member States regarding access to and the protection of confidential information disclosed in private enforcement proceedings. The Communication is not binding and does not modify the rules applicable in different Member States, but rather outlines a number of measures and tools national courts may employ to help protect confidential information.

On July 14, 2020, the Commission invited interested parties to comment on commitments offered by Aspen Pharma.[1] The commitments came following a Commission investigation opened on May 15, 2017 into excessive pricing for six life-saving cancer medications that Aspen purchased in 2009.[2]